GSK bets on tech to help boost lagging R&D as it looks to start 23andMe trial

Glaxo is a big entity but is seen as a laggard when it comes to R&D compared to its peers; Walmsley checked out projects early on she didn’t think would fit and has been signing deals with the likes of 23andMe, originally a DNA testing firm that has branched out rapidly into developing and out-licensing its own drugs.